Relapsed acute lymphoblastic leukemia (ALL) usually carries a dire prognosis. We evaluated the effectiveness and longterm complications of intensive rotational combination chemotherapy for late hematologic relapse (median, 16 months after elective cessation of therapy) among 34 children and young adults (ages 4 t o 23 years). Concurrent central nervous system (CNS) relapse was present in 3 cases and testic-
ular relapse in 4. Secondary therapy comprised an intensive five-drug reinduction (6 weeks) followed by continuation treatment with four drug pairs, rotated weekly in 4-week cycles over 120 weeks. Intrathecal chemotherapy (methotrexate, hydrocortisone, cytarabine) was given three times during reinduction and every 8 weeks during continuation. Treatment was electively discontinued at week 120 in the absence of detectable disease. Thirty-three patients (97%) attained a second complete remission. At a median followup of 9.3 years (range, 4.5 t o 11.4). estimates of 5-year sec-HE OPTIMAL TREATMENT for relapsed childhood T acute lymphoblastic leukemia (ALL) remains controversial. However, there is agreement that late hematologic relapses are associated with a better treatment outcome than relapses during or soon after treatment. In fact, the length of first hematologic remission has consistently emerged as the most important predictor of second remission duration after both hematologic and extramedullary relapse^."^ It is unclear, however, for how long one should retreat these patients, and what guidelines should be used for second elective cessation of therapy, particularly in view of reports of second relapses occumng several years after apparently successful secondary therapy.',* Long-term follow-up is clearly necessary to evaluate the effectiveness, and the associated morbidity, of any treatment regimen for relapsed ALL.
Our previous institutional protocol for patients with late marrow relapses yielded an estimated 5-year second eventfree survival of 31% (SE 17%). Twelve of the 26 patients treated on this protocol appear to be cured (4 in third remission), 12 to 15 years after the diagnosis of relap~e.~ We hypothesized that further intensification of both reinduction and continuation chemotherapy would improve these results.
Here we report the encouraging responses to a treatment regimen based on this premise. At a median follow-up of more than 9 years, it appears that at least two thirds of patients treated for late hematologic relapse will be longterm survivors. A parallel trial for children with isolated central nervous system (CNS) relapse has been described separately.6
MATERIALS AND METHODS
Between February 1983 and May 1990, a total of 34 patients with late hematologic relapses of ALL were treated on the St Jude Children's Research Hospital "R11" protocol. To participate in this mal, patients were required to have been off therapy for at least 6 months and to be in first hematologic relapse. Patients who had previously experienced an isolated CNS relapse (n = 2) or who had a combined marrow and CNS (n = 3) or testicular relapse (n = 4) were also eligible. The diagnosis of hematologic relapse was based on detection of greater than 25% leukemic blast cells in bone marrow (BM) aspirates, using previously described techniques.' CNS leuke-ond event-free and overall survival (+SE) are 65% f 8% and 79% f 7%. respectively. Eleven patients had a second relapse (9 marrow, 2 testicular) and one developed secondary myeloid leukemia. There have been no CNS relapses or deaths in remission. Treatment was well-tolerated and was given largely on an outpatient basis. Late effects are primarily endocrinologic; one child had a second malignant solid tumor (presumed related t o initial radiation therapy) that was treated successfully. Intensive treatment with alternating non-cross-resistant drug pairs for late hematologic relapses of ALL is effective and well-tolerated, and produces results similar t o those achieved in patients with newly diagnosed ALL. Event-free survival compares favorably with reports of other relapse regimens, including those incorporating bone marrow transplantation. 0 1996 b y The American Society of Hematology.
mia was diagnosed when leukemic blast cells were identified in Wright-stained centrifuged samples of cerebrospinal fluid (CSF), regardless of the CSF mononuclear cell count. This study was approved by the hospital's institutional review board, and written informed consent was obtained from patients, parents, or guardians, as appropriate.
Twenty-nine patients had received primary multiagent chemotherapy for ALL on St Jude Total Therapy Studies IX and X, which have been described in detail previo~sly.~.~ Five children were initially treated elsewhere: 2 on protocols of the Childrens Cancer Groupl"l' and 3 with combination chemotherapy similar to St Jude protocols. Briefly, initial therapy was based on postremission standard-dose 6-mercaptopurine and methotrexate in 7 cases; antimetabolite-based therapy with periodic high-dose methotrexate intensification in 13; standard-dose antimetabolites and postremission intensification with anthracyclines and epipodophyllotoxins in 10; periodic teniposide (VM-26) and cytarabine pulses in 2; and rotational combination chemotherapy including cyclophosphamide and epipodophyllotoxins in 2. CNS therapy comprised 18 to 24 Gy cranial irradiation plus intrathecal methohxate in 20 cases and highdose intravenous methotrexate (1 g/mz) plus intrathecal methotrexate followed by leucovorin rescue in 14 cases. The RI1 treatment schedule is illustrated in Table  1 . Reinduction therapy comprised five drugs (prednisone, vincristine, L-asparaginase, VM-26, cytarabine) administered over a 6-week period at full scheduled dosages, regardless of blood counts. Triple intrathecal therapy (methotrexate, hydrocortisone, and cytarabine) was given on days 1, 22, and 43 (plus days 8 and 15 for patients with combined marrow and CNS relapse). On day 43, a BM aspirate was performed to evaluate response. The four patients who had combined marrow and testicular relapses received 20 to 24 Gy bilateral gonadal irradiation (10 to 12 fractions over 14 to 16 days) after induction of hematologic remission. Continuation treatment, administered for 120 weeks after documentation of hematologic remission, was based on the use of multiple agents in rapid succession to avoid the development of drug resistance." Eight drugs were given in four pairs (etoposide + cyclophosphamide, 6-mercaptopurine + methotrexate, teniposide [VM-261 + cytarabine, and prednisone + vincristine) in weekly rotation for 4 weeks, with the rotation restarted at week 5. All patients received triple intrathecal chemotherapy every 8 weeks throughout continuation. Doses of all drugs except prednisone and vincristine were omitted if the absolute phagocyte count (polymorphonuclear cells + early myeloid cells + monocytes) was less than 0.5 X 109L or the platelet count was less than 50 X 109L, or if grade IIYIV stomatitis occurred. BM aspirates were obtained every 4 months and CSF examinations were done every 8 weeks. Chemotherapy was stopped if there was no evidence of disease after 120 weeks of continuation treatment. The three patients with combined marrow and CNS relapse received craniospinal irradiation (cranial 24 Gy, spinal 15 Gy in 16 fractions over 21 days) at week 120, before second elective cessation of therapy. None of these three patients had received preventive radiation during first remission.
Treatment.
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After therapy was discontinued. patients were seen for follow-up clinic visits every 4 months during the first year, every 6 months during the second year, and yearly thereafter. Examinations focused on possible late effects of treatment (eg, endocrine or neuropsychologic deficits) as well as the patients' continued leukemia-free status.
Second event-free survival (EFS) was defined as the interval from date of second remission to relapse in any site, life-threatening second-malignancy, or death (EFS was zero for patients whose disease did not enter remission). Second overall survival was defined as the time from diagnosis of first marrow relapse to death from any cause or to date of last contact. Final follow-up data for patients who were free of failure were obtained in February 1995. Life tables and Kaplan-Meier curves were constructed for second EFS and survival.'' The Cox proportional hazards model14 was used to examine the following potential predictors of EFS: sex, age at initial diagnosis, age at first marrow relapse, leukocyte count at initial diagnosis, site of relapse (marrow alone I' combined), duration of first hematologic remission, epipodophyllotoxin-intensified versus antimetabolite-based therapy, and prior cranial irradiation. Each prognostic factor was evaluated individually by a Cox univariate analysis because of the small number of events. These analyses showed no significant differences; hence, the P values were not adjusted for multiple significance tests. However. it should be pointed out that the lack of statistical significance does not necessarily mean that these factors do not have any prognostic value. Because of small sample sizes. these tests have limited statistical power. For example, a two-sided comparison of any two subgroups of equal size has 42% power to distinguish a 5-year EFS rate of 70% from a rate of 50% at the .OS significance level.
Sraristical merhods.
RESULTS
Characteristics of the 34 patients treated for late BM relapses of ALL, and summaries of their clinical course, are presented in Table 2 . At initial diagnosis, these patients ranged in age from 1 to 1 1 years (median, 4); age at relapse ranged from 4 to 23 years (median, 9) . There were slightly more male than female patients. Thirty-three patients were white and 1 (case 1) was black. The median white blood cell count was 10 X IO9& at initial diagnosis and 5.1 X IOy/ L at relapse.
The first hematologic remission in this group of patients had lasted 36 to 216 months (median, 45). The time since completion of initial therapy was 7 to 179 months (median, 16). Morphologic and immunophenotypic features of leukemic cells were similar at diagnosis and relapse in all cases. CDIO' B-lineage ALL was identified in 19 cases tested at both diagnosis and relapse and in 9 cases tested only at relapse. Six of 22 patients studied had a favorable DNA index (>1.16) at both initial diagnosis and relapse.
Of the 34 patients enrolled, 33 (97%) had attained complete hematologic remission at the end of the 6-week reinduction therapy. One patient died of Escherichia coli septicemia in the third week of reinduction therapy. At a median follow-up of 9.3 years (range, 4.5 to 11.4), the estimated 5year second EFS is 65% 2 8% and the estimated 5-year overall survival is 79% ~7 % (Fig 1) . DOD  DOD  NED  DOD  NED  NEDt  DOD  NED  NED  NED  DOD  NED  NED  NED  NED  NED  NED  NED  DOD  DOD  NED  NED  NED  DOD  NED*  NED  NED  Died  NED  NED  NED*  DOD  NED  NED Abbreviations: Dx, diagnosis; WBC, white blood count; DI, DNA index; CRT, cranial radiation therapy; HDMTX, high-dose MTX; Epipo, epipodophyllotoxins; HR, hematologic relapse; IF, induction failure; TA, testicular relapse; AML, acute myeloid leukemia; NED, no evidence of disease; DOD, died of disease.
Patients 10 and 24 were previously treated for an isolated CNS relapse but had remained in hematologic remission. Three of the 4 patients with combined marrow and testicular relapses remain in continuous second remission for 6,8, and 10 years, respectively, after testicular radiation therapy and secondary chemotherapy. Twenty-four patients (71%) are long-term survivors: 21 of these 24 are in continuous second hematologic remission. The length of the second remission exceeded that of the first remission in 19 cases. There have been no CNS relapses or deaths in remission. The two patients whose second remission ended with testicular relapse remain in complete remission after third elective cessation of therapy. Only one child survives after a second hematologic relapse, which followed second elective cessation of therapy. This patient (no. 6 in Table 2 ) received an allogeneic BM transplant in third hematologic remission, 8 years ago, and has been well since that time.
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From 834 RIVERA ET AL Analysis using the Cox proportional hazards model showed no significant impact on second EFS by any of the potential prognostic factors examined (sex, age at diagnosis, age at relapse, white blood cell count at diagnosis, DNA index at diagnosis, duration of first remission, combined v isolated BM relapse, and prior epipodophyllotoxin-intensified v antimetabolite-based therapy). However, given the sample size and limited power to detect differences between subgroups, the absence of statistical significance should not be equated with lack of clinical relevance.
Acute toxicity. During reinduction therapy, 96% of planned chemotherapy doses were administered. As expected, all patients developed profound myelosuppression. The median time to hematopoietic recovery after completion of reinduction therapy was 8 days (range, 1 to 18). In addition to the 1 case of fatal bacterial septicemia, 1 patient developed Aspergillus sinusitis but recovered with antifungal treatment. Stomatitis was infrequent. Eight patients required hospitalization (1 to 2 weeks duration) for febrile neutropenia and 10 received blood products. Seven patients required insulin for hyperglycemia secondary to treatment with prednisone and L-asparaginase. Two patients had L-asparaginase-associated cerebrovascular accidents; one of these patients has residual hemiparesis and the other recovered completely.
Continuation therapy was well tolerated, and the majority of treatment was administered on an outpatient basis. Myelosuppression was the most frequent cause of omitted chemotherapy doses (8% of planned doses). Platelet and absolute phagocyte counts recovered to acceptable levels within 1 week in 95% of myelosuppressive episodes. Hospital admissions were rare and usually brief, and few nonhematologic toxicities were observed. Grade 11-111 stomatitis occurred in 12 patients and was easily reversible; there were no instances of grade IV stomatitis. Moderate hypersensitivity reactions to epipodophyllotoxins (15 patients) were reversed with antihistamines, and no patient developed anaphylaxis.
Of the 24 long-term survivors (13 males, 11 females), 21 reported average or above-average academic progress through high school ( Table 3 ). Three of these 21 (all treated with cranial radiotherapy) received tutoring for minor academic difficulties. Three patients, including patient 30, who has constitutional trisomy 21, have required placement in special education classes for learning disabilities that predated the diagnosis of leukemia. Only 1 of the 10 patients who had serial neuropsychiatric evaluations showed a decline in functioning after treatment that included total body irradiation and BM transplantation (BMT). Other than the residual hemiparesis mentioned previously, no significant neurologic or psychologic problems have been identified among the long-term survivors.
Reduced growth velocity was identified in 14 individuals, 11 of whom received cranial radiotherapy as primary CNS therapy (n = 8) or relapse therapy (n = 3). Thirteen of these patients have reached their adult heights: five have short adult stature (ie, height at or below the fifth percentile), including the patient with trisomy 21. Three of these five patients had received cranial radiation as primary preventive therapy and one was treated with craniospinal radiation for Late effects. a combined CNS and hematologic relapse. Three boys, all of whom underwent cranial irradiation during their initial treatment, are receiving growth hormone therapy for reduced growth velocity. Five female and five male survivors are obese (increased body mass index for age). Hypothyroidism has been identified in only 1 patient, who was treated with 24 Gy cranial radiation. Pubertal development has progressed normally in 10 female survivors, all of whom are menstruating regularly. The young woman in third remission after allogeneic BMT has ovarian failure. Two female long-term survivors have delivered healthy full-term infants and one is currently pregnant. Four young men are hypogonadal as a consequence of testicular radiotherapy.
One patient has chronic active hepatitis B and C, following 36 donor exposures over a 5-year period. Another has avascular necrosis of the left hip and slipped capital femoral epiphysis.
Two patients developed a second malignant neoplasm. One died of secondary acute myeloid leukemia, which was diagnosed 9 months after the start of continuation therapy. The second, a young woman previously treated with cranial
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From THERAPY FOR RELAPSED ALL 835 radiation, developed a parotid mucoepidermoid carcinoma 67 months after the initial diagnosis of ALL. She remains in continuous hematologic remission and has had no recurrence of the radiation-related tumor after parotidectomy.
DISCUSSION
In this prospective study, intensive rotational combination chemotherapy was highly effective in treating patients who developed late hematologic relapses of childhood ALL. With long-term follow-up (median, 9.3 years), the estimated 5year second EFS is 65% (SE 8%). Thus, two thirds of these patients are probably cured of their leukemia. These results are superior to those of our prior relapse trial (5-year second EFS 3 1 %) 5 and a parallel Pediatric Oncology Group study (4-year second EFS 37%),15 both of which used a less intensive three-drug reinduction therapy. Although direct comparisons are not possible in view of differences in patient populations and treatment histories, these results are similar to those from studies of high-dose chemotherapy, total body irradiation, and allogeneic BMT for patients in second remission after a late hematologic relapse. 16 Uderzo et all6 recently reported a large series of pediatric patients with hematologic relapses of ALL in which allogeneic BMT was superior to chemotherapy among those children who had a short first remission. However, the data did not demonstrate superiority of allografts in children with an initial remission of 30 or more months (relative risk [RR] = .94; P = .92, 95% confidence interval [CI], 0.30 to 2.96). Barrett et all7 used the criteria of age and leukocyte count at diagnosis, sex, immunophenotype, and length of first remission to match 76 patients enrolled in Pediatric Oncology Group chemotherapy relapse protocols with children who underwent BMT in a variety of institutions. Overall, BMT produced a significantly superior 5-year leukemia-free survival (40% [SE 3%] v 17% [SE 3%], P < .01). However, this difference was less marked for patients who had a prolonged initial remission (5-year leukemia-free survival, 32% [SE 6%] for the chemotherapy-treated patients and 53% [SE 7%] for the transplant group; P value not given). Therefore, the investigators suggested that, in patients with long initial remissions, it might be reasonable to defer transplantation until a subsequent relapse occurred. Investigators from the Berlin-Frankfurt-Munster group have reported a 7-year second EFS of 47% (SE 12%) for 27 patients treated with allogeneic transplantation for late marrow relapse," an outcome no better than that in our chemotherapy-treated patients. Taken together, the available data suggest an approach based on intensified chemotherapy for patients with late marrow relapses, with allogeneic marrow transplant reserved for patients who relapse early or who have specific high-risk features such as the Philadelphia chromosome.
Some leukemia specialists recommend autologous marrow transplants for patients with relapsed ALL in second or subsequent hematologic remission. The Boston group'' recently reported a 3-year EFS (median follow-up, 3.3 years) of 50% (SE 9%) for 31 patients treated with high-dose chemotherapy, total body irradiation, and infusion of antibodytreated autologous marrow in second hematologic remission. Patients in this study (which also included children in third or subsequent relapse) had a first remission duration of at least 24 months and a B-progenitor CD19+/CDlO+ immunophenotype. Our findings suggest that similar results could be obtained with chemotherapy alone in children with these features who are in first hematologic relapse after a prolonged initial remission.
Regardless of the duration of prior remission, effective CNS preventive therapy at relapse is essential, as hematologic relapse apparently nullifies the effects of initial therapy for subclinical meningeal leukemia. However, the specific therapy must be selected carefully, in view of the potential for severe neurotoxicity." We previously reported that prolonged periodic administration of intrathecal chemotherapy effectively prevented CNS relapses during second hematologic remission, even in the context of less intensive postremission therapy.' The Berlin-Frankfurt-Munster group recommends that all children with late hematologic relapse receive 12 to 18 Gy cranial irradiation combined with shortterm intrathecal chemotherapy. In their 1987 relapse study, estimated 6-year second EFS rates were 46% for patients who received cranial irradiation versus 18% for those who did not." However, to our knowledge, the late sequelae of these therapies have not been reported.
None of our patients treated with multiple courses of triple intrathecal therapy, without craniospinal radiation, ended second remission with a CNS relapse. Craniospinal radiation was used only for the 3 patients who had combined marrow and CNS relapses (2 of whom survive, without long-term neurotoxicity, at 3 and 10 years posttreatment, respectively). Pharmacokinetic studies at St. Jude have demonstrated good CNS penetration of intravenous epipodophyllotoxins,22 which may be an additional factor in preventing meningeal relapses. Hence, we recommend that cranial irradiation be reserved for the small percentage of patients who have overt CNS leukemia at the time of hematologic relapse.
The treatment program described here was well tolerated, permitting delivery of chemotherapy as scheduled and thus enhancing dose intensity. Most therapy was delivered on an outpatient basis. There were no deaths from acute toxicity during continuation therapy. Long-term follow-up to detect late failures and treatment sequelae is mandatory in studies of therapy for relapsed childhood ALL. Late effects, particularly severe organ and secondary malignan~ies,~~ are a major concern, but data on sequelae are often unavailable when treatment results are reported. For these reasons, we chose to follow our patients for a minimum of e 5 years before reporting treatment outcome.
When this study was designed, the carcinogenic potential of the topoisomerase I1 inhibitors had not been d e~c r i b e d .~~ Fortunately, however, irradiation was restricted to patients with extramedullary disease, anthracyclines were not used, and the epipodophyllotoxins were administered every 2 weeks-a schedule that has since been associated with a lower risk of secondary leukemia compared with more frequent administration.26 The one case of secondary acute myeloid leukemia in our series was diagnosed only 9 months after second remission induction and may have been related to the patient's initial treatment, which comprised alkylating agents, anthracyclines, epipodophyllotoxins, and CNS irradi-For personal use only. on October 22, 2017. by guest www.bloodjournal.org From ation. A second patient has been successfully treated for a parotid mucoepidermoid carcinoma, presumed to have resulted from cranial radiation therapy during initial treatment. Other cumulative long-term sequelae in this series primarily comprise endocrinopathies and learning problems. These deficits are unfortunate, but must be viewed in the context of the overall outcome of this treatment regimen and the absence of deaths from toxicity during postremission therapy.
We failed to identify patient or treatment characteristics that were predictive of second remission duration. Similarities among our patients in terms of potential predictive features such as immunophenotype and duration of first remission (>36 months in all cases), along with the relatively small sample size and overall good results, may account for the absence of statistically significant findings. Although there is no statistical evidence that the type of prior therapy affected outcome, it is worth noting the excellent long-term outcome of 10 of 13 patients initially treated with antimetabolite-based therapy that included high-dose methotrexate intensification.
The use of rapidly rotated drug pairs, most given parenterally, represented a marked departure from the then-standard postremission treatment (ie, standard-doses, primarily oral, of 6-mercaptopurine and methotrexate). Once adequate tolerance was established, we extended this approach to the treatment of newly diagnosed patients in St Jude Total Therapy Study XI-a protocol that was very successful, especially among higher-risk patients2' These observations underscore the importance of relapse studies in developing effective new therapies for leukemia. We have also found this relapse therapy highly effective in the treatment of isolated CNS relapses, especially in patients initially treated with antimetabolite-based therapy, with a 5-year second EFS of 68% (SE IO%).'
Useful modifications of the chemotherapy regimen described here (in addition to parenteral versus oral methotrexate), might include substitution of dexamethasone for prednisone because of its better CNS penetration." and/or postremission intensification using high-dose L-asparaginase." A second course of reinduction treatment to reinforce remission might also be of benefit.",'" Other possibilities include high-dose intravenous chemotherapy with methotrexate, cytarabine, or both. However, doses and schedules must be carefully planned, especially in patients who have received prior CNS radiation therapy, to decrease the risk of neurotoxicity.
With current information, it remains difficult to determine the optimal time for second cessation of therapy. In this study, 8 of the I 1 relapses occurred after elective cessation of therapy. Thus, it appears that, in about one fourth of our patients, this therapy was not sufficiently intensive or was stopped too soon. These clinical findings, along with the inherent biologic differences in leukemic cell growth properties, suggest the need to consider individualized treatment intensity and duration. To address this issue, we have begun a prospective study of the predictive value of minimal residual disease detection. If these studies prove to be reliably predictive, it may be possible to identify patients who require extended or alternative therapies.
Our experience suggests that patients with late hematologic relapses of ALL can be effectively treated with chemotherapy, which should be as intensive as that used in newly diagnosed patients with high-risk leukemia, and that CNS radiation therapy can be reserved for patients who develop overt meningeal relapse. We prefer to consider allogeneic BMT only for patients who have an early first relapse (or relapse after prolonged initial remission and subsequent retreatment), or who have known high-risk features such as the Philadelphia chromosome.
The results obtained with this therapy for late relapses of ALL are not markedly different from those achieved in trials for newly diagnosed ALL, and compare favorably with other reports of treatment for patients in second remission. The intensive relapse therapy was generally well-tolerated and may be particularly well-suited for late relapses following antimetabolite-based therapy -an approach currently used by several groups in the United States and elsewhere to treat children with intermediate-or better-risk B-progenitor ALL.
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